Practice Management News

The American Board of Internal Medicine and the Accreditation Council for Continuing Medical Education have teamed up to allow physicians to receive Maintenance of Certification credits from traditional continuing medical education courses they have taken, according to a press release.

It is estimated that roughly 126 million adults in the U.S. regularly experience varying levels of pain, according to recently published data in the Journal of Pain.

Over the past 5 years, satisfaction with electronic health records has declined among physicians, despite being used by a great proportion of them, according to recently published survey results from AmericanEHR Partners and AMA. 

Tekmira Pharmaceuticals announced that it has changed its corporate name to Arbutus Biopharma Corporation as of August 3 and are now a company focusing completely on developing a cure for hepatitis B virus infection, according to a press release.

In a new FDA Safety Communication report, the FDA provides supplemental measures for enhancing duodenoscope reprocessing for hospitals and health care facilities that use duodenoscopes, in an effort to continue reducing the risk of infection and increase the safety of endoscopic retrograde cholangiopancreatography medical devices.

I speak with health care practices on a regular basis. During these conversations, physicians usually ask a range of questions to help determine whether they should incorporate third-party patient financing into their practice.

The American Academy of Family Physicians and the American College of Physicians has announced their support of the AllTrials campaign, joining 595 other organizations from around the world, according to a recent press release.

Due to expanded health insurance coverage from the ACA, as well as the aging population and economic growth, health care spending is projected to increase at a rate of 5.8% annually between 2014 and 2024, according to recently published data in Health Affairs. 

World Hepatitis Day is July 28. To acknowledge how far treatment and the drug pipeline for hepatitis C and other strands of the virus infection has come, Healio.com/Hepatology created a list of drugs and regimens that have been approved by the FDA or are in the pipeline to treat the infection from the past year.

Nearly 10% of adverse events are not reported to the FDA within the 15-day period drug companies have to disclose the events, according to recently published data.